Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Maintenance Organizations | 8 | 2007 | 658 | 0.360 |
Why?
|
| Treatment Refusal | 5 | 2008 | 429 | 0.240 |
Why?
|
| Patient Compliance | 7 | 2009 | 2688 | 0.240 |
Why?
|
| Drug Utilization | 7 | 2008 | 1186 | 0.210 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2925 | 0.210 |
Why?
|
| Benzodiazepines | 5 | 2007 | 1132 | 0.170 |
Why?
|
| RNA Polymerase II | 1 | 2003 | 537 | 0.160 |
Why?
|
| Drug Therapy | 3 | 2008 | 503 | 0.150 |
Why?
|
| Drug Prescriptions | 5 | 2008 | 1669 | 0.150 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2007 | 467 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2008 | 5073 | 0.140 |
Why?
|
| Research Design | 3 | 2008 | 6174 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2003 | 871 | 0.130 |
Why?
|
| Drug Costs | 4 | 2008 | 1183 | 0.120 |
Why?
|
| Legislation, Drug | 2 | 2007 | 214 | 0.120 |
Why?
|
| Antidepressive Agents | 4 | 2007 | 2896 | 0.110 |
Why?
|
| Anti-Anxiety Agents | 2 | 2007 | 397 | 0.110 |
Why?
|
| Medical Indigency | 3 | 2008 | 63 | 0.110 |
Why?
|
| Prescriptions | 2 | 2008 | 385 | 0.110 |
Why?
|
| Medicare Part D | 2 | 2008 | 354 | 0.110 |
Why?
|
| Postnatal Care | 3 | 2004 | 260 | 0.100 |
Why?
|
| Health Policy | 5 | 2008 | 2682 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5789 | 0.100 |
Why?
|
| Diabetes Mellitus | 6 | 2009 | 5835 | 0.090 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2007 | 348 | 0.080 |
Why?
|
| Hypoglycemic Agents | 5 | 2009 | 3085 | 0.080 |
Why?
|
| Medicaid | 6 | 2008 | 2814 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 94 | 0.080 |
Why?
|
| Sampling Studies | 1 | 2008 | 615 | 0.070 |
Why?
|
| Hip Fractures | 2 | 2007 | 988 | 0.070 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 127 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2008 | 6338 | 0.070 |
Why?
|
| Marketing | 1 | 2008 | 220 | 0.060 |
Why?
|
| Depressive Disorder | 3 | 2007 | 3735 | 0.060 |
Why?
|
| Length of Stay | 3 | 2004 | 6418 | 0.060 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 164 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 452 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 321 | 0.060 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 71 | 0.060 |
Why?
|
| Pirenzepine | 1 | 2003 | 116 | 0.050 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2003 | 42 | 0.050 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2003 | 41 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2003 | 67 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 496 | 0.050 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 3066 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 248 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2003 | 277 | 0.050 |
Why?
|
| Histidine | 1 | 2003 | 308 | 0.050 |
Why?
|
| Haloperidol | 1 | 2003 | 389 | 0.050 |
Why?
|
| Patient Discharge | 3 | 2003 | 3442 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1141 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2006 | 697 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 180 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 1130 | 0.050 |
Why?
|
| Medicare | 3 | 2008 | 6765 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2008 | 12043 | 0.040 |
Why?
|
| Disabled Persons | 2 | 2007 | 1226 | 0.040 |
Why?
|
| Alanine | 1 | 2003 | 609 | 0.040 |
Why?
|
| Warfarin | 1 | 2008 | 1477 | 0.040 |
Why?
|
| Massachusetts | 7 | 2007 | 8833 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 655 | 0.040 |
Why?
|
| Serine | 1 | 2003 | 830 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2008 | 12142 | 0.040 |
Why?
|
| New York | 3 | 2007 | 874 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2004 | 851 | 0.040 |
Why?
|
| Breast Feeding | 2 | 2004 | 1354 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 2265 | 0.040 |
Why?
|
| Aftercare | 1 | 2003 | 913 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 1149 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2003 | 1175 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1755 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 2546 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2003 | 3087 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 3792 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 2315 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5034 | 0.030 |
Why?
|
| Disease Management | 1 | 2006 | 2506 | 0.030 |
Why?
|
| Transfection | 1 | 2003 | 5766 | 0.030 |
Why?
|
| New Jersey | 2 | 2007 | 295 | 0.030 |
Why?
|
| Health Expenditures | 2 | 2008 | 2361 | 0.030 |
Why?
|
| Humans | 33 | 2009 | 760617 | 0.030 |
Why?
|
| Binding Sites | 1 | 2003 | 6051 | 0.030 |
Why?
|
| Health Care Surveys | 3 | 2007 | 2423 | 0.030 |
Why?
|
| Male | 24 | 2009 | 360358 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 1452 | 0.030 |
Why?
|
| Aged | 16 | 2009 | 169042 | 0.030 |
Why?
|
| Female | 25 | 2009 | 392148 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2008 | 7798 | 0.030 |
Why?
|
| Middle Aged | 18 | 2009 | 220584 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2008 | 4785 | 0.030 |
Why?
|
| State Health Plans | 2 | 2006 | 219 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3431 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2004 | 1937 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2003 | 8311 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 5061 | 0.020 |
Why?
|
| Demography | 2 | 2006 | 1643 | 0.020 |
Why?
|
| Anxiety | 1 | 2006 | 4570 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4354 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2006 | 4321 | 0.020 |
Why?
|
| Protein Binding | 1 | 2003 | 9345 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2006 | 3805 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2009 | 4010 | 0.020 |
Why?
|
| Longitudinal Studies | 4 | 2009 | 14591 | 0.020 |
Why?
|
| Adult | 15 | 2009 | 220969 | 0.020 |
Why?
|
| United States | 9 | 2008 | 72272 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 6929 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 7583 | 0.020 |
Why?
|
| New Hampshire | 1 | 2008 | 175 | 0.020 |
Why?
|
| Maine | 1 | 2008 | 146 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2006 | 1315 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 453 | 0.020 |
Why?
|
| Cohort Studies | 5 | 2008 | 41457 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 48 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 5091 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 4764 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2006 | 102 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 4845 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2008 | 308 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 112 | 0.020 |
Why?
|
| Oxycodone | 1 | 2006 | 139 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 58894 | 0.020 |
Why?
|
| Self Administration | 1 | 2006 | 387 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 12116 | 0.010 |
Why?
|
| Methadone | 1 | 2006 | 321 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 2004 | 116 | 0.010 |
Why?
|
| Age Factors | 3 | 2007 | 18381 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2004 | 97 | 0.010 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 251 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 151 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 741 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 650 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10754 | 0.010 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 335 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 655 | 0.010 |
Why?
|
| Logistic Models | 2 | 2008 | 13245 | 0.010 |
Why?
|
| Retrospective Studies | 5 | 2009 | 80566 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2007 | 905 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2278 | 0.010 |
Why?
|
| Personality Inventory | 1 | 2003 | 1018 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 368 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Comorbidity | 2 | 2007 | 10505 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 786 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 351 | 0.010 |
Why?
|
| Cost Control | 1 | 2002 | 627 | 0.010 |
Why?
|
| Prevalence | 2 | 2007 | 15689 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 835 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1739 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 1411 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2004 | 26180 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4570 | 0.010 |
Why?
|
| Data Collection | 1 | 2008 | 3315 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 486 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 30016 | 0.010 |
Why?
|
| Psychometrics | 1 | 2008 | 3060 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4037 | 0.010 |
Why?
|
| Adolescent | 4 | 2008 | 88234 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 2486 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 460 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4614 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6188 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2689 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 2379 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 648 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1852 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1375 | 0.010 |
Why?
|
| Psychiatry | 1 | 2007 | 1693 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 168201 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 3239 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3567 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 26049 | 0.010 |
Why?
|
| Social Class | 1 | 2003 | 1992 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 6016 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12447 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4366 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2003 | 2090 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2003 | 2595 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 39063 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7237 | 0.010 |
Why?
|
| Insulin | 1 | 2007 | 6593 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4571 | 0.010 |
Why?
|
| Young Adult | 2 | 2008 | 59179 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 9311 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9313 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3244 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 22148 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2007 | 4668 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 14389 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2778 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10432 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 20074 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 4075 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12334 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 5430 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 16967 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 12943 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2002 | 3269 | 0.000 |
Why?
|
| Incidence | 1 | 2007 | 21337 | 0.000 |
Why?
|
| Phenotype | 1 | 2006 | 16571 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22115 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18221 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 7871 | 0.000 |
Why?
|
| Hospitalization | 1 | 2002 | 10704 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 23416 | 0.000 |
Why?
|
| Child | 1 | 2008 | 80079 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 81368 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 64568 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 74115 | 0.000 |
Why?
|
| Neoplasms | 1 | 2003 | 22131 | 0.000 |
Why?
|
Concepts
(209)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_